Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a
company focused on developing, marketing, and selling a variety of
men’s health and wellness products via a secure telemedicine
platform, including its uniquely formulated hair growth product
(‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited
to announce that it is offering 2 months of free ‘PRIME’ by
MangoRx, Powered by Kyzatrex®️ (“PRIME”) (a $498 value) for the
first 1,000 male subscribers who express interest in subscribing to
the oral testosterone replacement protocol.
Those interested in taking advantage of this
exclusive offer simply need to visit the sign-up page at
https://www.mangorx.com/prime-sign-up/ and submit basic demographic
information. Interested subscribers will also be prompted to
preorder a minimally invasive FDA approved at-home blood collection
test kit through their nationwide lab partnership with Trybe Labs,
which is being offered to MangoRx subscribers at preferred
discounted prices.
Jacob Cohen, MangoRx’s Co-Founder and CEO,
noted, “in anticipation of our official PRIME launch this month, we
are excited to offer this one-time promotion to our first 1,000
interested subscribers. We are also very excited about showcasing
Prime and all its amazing benefits through our marquee sponsorship
with Barstool Sports for the week leading up to the Big Game in Las
Vegas and for many months thereafter on the various Barstool live
and streaming programs, podcasts, and events.”
Dr. Douglas Christianson, MangoRx’s advisory
board member, noted, "as testosterone is a Schedule III substance,
the Company has undergone additional measures - both internally and
with its 3rd party doctor’s network and pharmacy – to ensure both
the safety of its customers and its compliance with all state and
federal healthcare regulatory agencies. Making sure that all of
these controls and safeguards are in place is paramount to
MangoRx’s official launch anticipated to be later this month.”
PRIME represents a critical expansion into a new
vertical with massive market potential and very little competition
on the consumer side, while remaining completely consistent with
MangoRx’s established identity as a company committed to providing
new and innovative pharmaceutical based solutions helping men
achieve optimal performance in all areas of life. With the
Company’s established marketing and telemedicine infrastructure in
place, MangoRx is ready to hit the ground running and take PRIME to
patients in need across the country later this month. All orders
will be reviewed and, pending approval, fulfilled, then discreetly
shipped via MangoRx’s URAC accredited mail order partner pharmacy
directly to the patient’s doorstep.
‘PRIME’, by MangoRx, powered by Kyzatrex®️, an
innovative FDA-approved oral Testosterone Replacement Therapy (TRT)
product, is a prescription drug that is used to treat adult men who
have low or no testosterone levels due to certain medical
conditions and is one of only three FDA approved TRT treatments
that is delivered orally--as opposed to the traditional, invasive,
and inconvenient injection-based drug delivery protocol. ‘PRIME’,
by MangoRx, powered by Kyzatrex®️ delivers testosterone in a
softgel capsule that is absorbed primarily via the lymphatic
system, avoiding liver toxicity.
The benefits of ‘PRIME,’ powered by Kyzatrex®️,
over traditional injectable TRTs include enhanced vitality,
improved mood, sharper cognition, optimized physical performance,
and balanced hormonal levels at 96% efficacy by day 90, as
demonstrated in Phase 3 clinical research by Marius
Pharmaceuticals. With ‘PRIME,’ MangoRx will expand broad-based
consumer access to this revolutionary therapy.
PRIME will be available to MangoRx customers at
a price of $199/month with eligibility to receive an additional 10%
discount per month if subscribed to another MangoRx product (e.g.
‘Mango’ for erectile function or ‘Grow’ for hair growth).
About MangoRx
MangoRx is focused on developing a variety of
men's health and wellness products and services via a secure
telemedicine platform. To date, the Company has identified men's
wellness telemedicine services and products as a growing sector and
especially related to the area of erectile dysfunction (ED) and
hair growth. Interested consumers can use MangoRx’s telemedicine
platform for a smooth experience. Prescription requests will be
reviewed by a physician and, if approved, fulfilled and discreetly
shipped through MangoRx’s partner compounding pharmacy and right to
the patient’s doorstep.
To learn more about MangoRx’s mission and other
products, please visit www.MangoRx.com or on social media
@Mango.Rx.
Cautionary Note Regarding
Forward-Looking StatementsCertain statements made in this
press release contain forward-looking information within the
meaning of applicable securities laws, including within the meaning
of the Private Securities Litigation Reform Act of 1995
("forward-looking statements"). These forward-looking statements
represent the Company's current expectations or beliefs concerning
future events and can generally be identified using statements that
include words such as "estimate," "expects," "project," "believe,"
"anticipate," "intend," "plan," "foresee," "forecast," "likely,"
"will," "target" or similar words or phrases. These forward-looking
statements are subject to risks, uncertainties and other factors,
many of which are outside of the Company's control which could
cause actual results to differ materially from the results
expressed or implied in the forward-looking statements, including,
but not limited to; our ability to obtain additional funding and
generate revenues to support our operations; risks associated with
our ED product which have not been, and will not be, approved by
the U.S. Food and Drug Administration ("FDA") and have not had the
benefit of the FDA's clinical trial protocol which seeks to prevent
the possibility of serious patient injury and death; risks that the
FDA may determine that the compounding of our planned products does
not fall within the exemption from the Federal Food, Drug, and
Cosmetic Act ("FFDCA Act") provided by Section 503A; risks
associated with related party relationships and agreements; the
effect of data security breaches, malicious code and/or hackers;
competition and our ability to create a well-known brand name;
changes in consumer tastes and preferences; material changes and/or
terminations of our relationships with key parties; significant
product returns from customers, product liability, recalls and
litigation associated with tainted products or products found to
cause health issues; our ability to innovate, expand our offerings
and compete against competitors which may have greater resources;
our significant reliance on related party transactions; the
projected size of the potential market for our technologies and
products; risks related to the fact that our Chairman and Chief
Executive Officer, Jacob D. Cohen and President, Jonathan Arango,
combined have majority voting control over the Company; risks
related to the significant number of shares in the public float,
our share volume, the effect of sales of a significant number of
shares in the marketplace, and the fact that the majority of our
shareholders paid less for their shares than the public offering
price of our common stock in our recent initial public offering;
the fact that we have a significant number of outstanding warrants
to purchase shares of common stock at $1.00 per share, the resale
of which underlying shares have been registered under the
Securities Act of 1933, as amended; our ability to build and
maintain our brand; cybersecurity, information systems and fraud
risks and problems with our websites; changes in, and our
compliance with, rules and regulations affecting our operations,
sales, marketing and/or our products; shipping, production or
manufacturing delays; regulations we are required to comply with in
connection with our operations, manufacturing, labeling and
shipping; our dependency on third-parties to prescribe and compound
our ED product; our ability to establish or maintain relations
and/or relationships with third-parties; potential safety risks
associated with our Mango ED product, including the use of
ingredients, combination of such ingredients and the dosages
thereof; the effects of high inflation, increasing interest rates
and economic downturns, including potential recessions, as well as
macroeconomic, geopolitical, health and industry trends, pandemics,
acts of war (including the ongoing Ukraine/Russian conflict) and
other large-scale crises; our ability to protect intellectual
property rights; our ability to attract and retain key personnel to
manage our business effectively; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; overhang
which may reduce the value of our common stock; volatility in the
trading price of our common stock; and general consumer sentiment
and economic conditions that may affect levels of discretionary
customer purchases of the Company's products, including potential
recessions and global economic slowdowns. Although we believe that
our plans, intentions and expectations reflected in or suggested by
the forward-looking statements we make in this release are
reasonable, we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties.
More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended September 30, 2023. These
filings are available at www.sec.gov and at our website at
https://www.mangoceuticals.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
FOR PUBLIC RELATIONSLucky Break Public RelationsSahra
SimpsonSahra@luckybreakpr.com (323) 602-0091 ext. 704
FOR INVESTOR RELATIONSMangoceuticals Investor RelationsEmail:
investors@mangorx.com
MEDIA CONTACTPHOENIX MGMT Marketing &
Consultinginfo@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Mangoceuticals (NASDAQ:MGRX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024